Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Antibodies against cell adhesion molecules and neural structures in paraneoplastic neuropathies

  • Siles, Ana M..
  • Martínez Hernández, Eugenia
  • Araque, Josefa
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Illa, Isabel|||0000-0002-2186-2684
  • Graus Ribas, Francesc|||0000-0002-8924-8322
  • Querol, Luis|||0000-0002-4289-8264
Paraneoplastic neurological syndromes () are rare neurological disorders in which ectopic expression of neural antigens by a tumor results in an autoimmune attack against the nervous system. Onconeural antibodies not only guide diagnosis but may also help detecting underlying malignancies. Our project aims to uncover new potential antibodies in paraneoplastic neuropathies (). Thirty-four patients fulfilling diagnostic criteria of possible (n = 9; 26.5%) and definite (n = 25; 73.5%) without onconeural antibodies and 28 healthy controls were included in our study. Sera were tested for known antibodies against neural cell adhesion molecules and screened for novel IgG and IgM reactivities against nerve components: dorsal root ganglia () neurons, motor neurons, and Schwann cells. Patients showing autoantibodies against any of these cell types were used for immunoprecipitation () studies. Overall, 9 (26.5%) patients showed significant reactivity against neurons, motor neurons, or Schwann cells, whereas 5 (17.9%) healthy controls only showed moderate reactivity. Compared with control sera, serum samples from patients with paraneoplastic sensory-motor neuropathies had a higher frequency of IgM antibodies against Schwann cells (0% vs. 40%; P = 0.0028). No novel antigens were identified from our experiments. Antibodies against the neural adhesion molecules 1, 155, 140, 186, 1, L1, and the 1/1 complex were not detected in patients with . One (2.9%) patient with and thymoma had 2 antibodies. Almost 30% of patients with harbor antibodies targeting neural structures, suggesting that novel neoplasm-associated antigens remain to be discovered.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy

  • Querol, Luis|||0000-0002-4289-8264
  • Siles, Ana M..
  • Alba-Rovira, Roser|||0000-0003-3308-5787
  • Jáuregui, Agustín
  • Devaux, Jérôme|||0000-0001-6383-4334
  • Faivre-Sarrailh, Catherine
  • Araque, Josefa
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Nogales, Gisela|||0000-0002-7414-212X
  • Navas Madroñal, Miquel|||0000-0003-2984-1471
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Illa, Isabel|||0000-0002-2186-2684
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous disease in which diverse autoantibodies have been described but systematic screening has never been performed. Detection of CIDP-specific antibodies may be clinically useful. We developed a screening protocol to uncover novel reactivities in CIDP. Sixty-five CIDP patients and 28 controls were included in our study. Three patients (4.6%) had antibodies against neurofascin 155, four (6.2%) against contactin-1 and one (1.5%) against the contactin-1/contactin-associated protein-1 complex. Eleven (18.6%) patients showed anti-ganglioside antibodies, and one (1.6%) antibodies against peripheral myelin protein 2. No antibodies against myelin protein zero, contactin-2/contactin-associated protein-2 complex, neuronal cell adhesion molecule, gliomedin or the voltage-gated sodium channel were detected. In IgG experiments, three patients (5.3%) showed a weak reactivity against motor neurons; 14 (24.6%) reacted against DRG neurons, four of them strongly (7.0%), and seven (12.3%) reacted against Schwann cells, three of them strongly (5.3%). In IgM experiments, six patients (10.7%) reacted against DRG neurons, while three (5.4%) reacted against Schwann cells. However, results were not statistically significant when compared to controls. Immunoprecipitation experiments identified CD9 and L1CAM as potential antigens, but reactivity could not be confirmed with cell-based assays. In summary, we describe a diverse autoantibody repertoire in CIDP patients, reinforcing the hypothesis of CIDP's pathophysiological heterogeneity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy

  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Simón Talero, Manuel J.
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Moga, Esther|||0000-0003-4264-6910
  • Juárez Rubio, Cándido|||0000-0003-2235-9893
  • Illa, Isabel|||0000-0002-2186-2684
  • Querol, Luis|||0000-0002-4289-8264
Antibodies against myelin-associated glycoprotein (MAG) almost invariably appear in the context of an IgM monoclonal gammopathy associated neuropathy. Very few cases of anti-MAG neuropathy lacking IgM-monoclonal gammopathy have been reported. We investigated the presence of anti-MAG antibodies in 69 patients fulfilling diagnostic criteria for CIDP. Anti-MAG antibodies were tested by ELISA and confirmed by immunohistochemistry. We identified four (5.8%) anti-MAG positive patients without detectable IgM-monoclonal gammopathy. In two of them, IgM-monoclonal gammopathy was detected at 3 and 4-year follow-up coinciding with an increase in anti-MAG antibodies titers. In conclusion, anti-MAG antibody testing should be considered in chronic demyelinating neuropathies, even if IgM-monoclonal gammopathy is not detectable.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Chronic inflammatory demyelinating polyneuropathy associated with contactin-1 antibodies in a child

  • Carrera-García, Laura|||0000-0003-4762-7591
  • Natera-De Benito, D.
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Colomer, Jaume
  • Nascimento, A.
  • Saiz, Albert|||0000-0002-5793-8791
  • Dalmau, Josep|||0000-0001-5856-2813
  • Querol, Luis|||0000-0002-4289-8264
  • Armangue, Thais|||0000-0001-6192-6171
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Caveats and pitfalls of SOX1 autoantibody testing with a commercial line blot assay in paraneoplastic neurological investigations

  • Ruiz-García, Raquel
  • Martínez Hernández, Eugenia
  • García-Ormaechea, Milagros
  • Español-Rego, Marta|||0000-0001-5497-2276
  • Sabater, Lidia
  • Querol, Luis|||0000-0002-4289-8264
  • Illa, Isabel|||0000-0002-2186-2684
  • Dalmau, Josep|||0000-0001-5856-2813
  • Graus Ribas, Francesc|||0000-0002-8924-8322
SOX1 autoantibodies are considered markers of small cell lung cancer (SCLC) and paraneoplastic neurological syndromes (PNS) and are usually determined by commercial line blot in many clinical services. Recent studies suggested that SOX1 autoantibodies also occur in patients with neuropathies unrelated to SCLC, questioning the value of SOX1 autoantibodies as paraneoplastic biomarkers. Here, we compared the specificity and sensitivity of a commercial line blot (Euroimmun, Lübeck, Germany) with those of an in house cell-based assay (CBA) with HEK293 cells transfected with SOX1. Overall, 210 patients were included in the study, 139 patients with polyneuropathies without SCLC, and 71 with disorders associated with SOX1 autoantibodies detected with the in-house CBA. Forty one of these 71 cases had been referred to our laboratory for onconeuronal antibody assessment and 30/71 were patients with known PNS and SCLC. None of the patients with polyneuropathies had SOX1 autoantibodies by either line blot or CBA (specificity of the immunoblot: 100%; 95%C.I.: 97.8-100). Among the 71 patients with CBA SOX1 autoantibodies, only 53 were positive by line blot (sensitivity: 74.6%; 95%C.I.: 62.9-84.2). Lung cancer was detected in 37/41 (90%; 34 with SCLC) patients referred for onconeuronal antibody assessment and 34 of them also had a PNS. Our study confirms the association of SOX1 autoantibodies with SCLC and PNS. The line blot test misses 25% of the cases; therefore, to minimize the frequency of false negative results we recommend the use of a confirmatory test, such as CBA, in patients suspected to have a SCLC-related PNS.